Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03008304 | High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00813163 | Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer | completed | Phase 2 | 41 | PharmaEngineINDUSTRY | 2 | Sep 6, 2019 | clinicaltrials |
| A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors(KAMELEON) |
| completed |
| Phase 2 |
| 20 |
| Hoffmann-La RocheINDUSTRY |
| 4 |
| Aug 28, 2019 |
| clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 55 | Incyte CorporationINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01132755 | Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage | completed | Phase 2 | 112 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01893801 | Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | completed | Phase 1 / Phase 2 | 25 | Pancreatic Cancer Research TeamOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT00219557 | AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 111 | PfizerINDUSTRY | 8 | May 14, 2019 | clinicaltrials |
| NCT01128296 | Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas | completed | Phase 1 / Phase 2 | 35 | Amer ZureikatOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT01088815 | Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | completed | Phase 2 | 98 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT00923299 | Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine(THERAPY) | completed | Phase 1 / Phase 2 | 33 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00735917 | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | Apr 2, 2019 | clinicaltrials |
| NCT01978184 | Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine | completed | Phase 2 | 104 | Nathan Bahary, MDOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00637247 | A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer | completed | Phase 2 | 142 | AmpliMed CorporationINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00711997 | Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 9 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Mar 20, 2019 | clinicaltrials |
| NCT02301143 | Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)(LAPACT) | completed | Phase 2 | 107 | CelgeneINDUSTRY | 5 | Mar 20, 2019 | clinicaltrials |
| NCT01233375 | Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | completed | Phase 2 | 19 | Clovis Oncology, Inc.INDUSTRY | 1 | Mar 11, 2019 | clinicaltrials |
| NCT02440958 | Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | completed | Phase 2 | 50 | Yonsei UniversityOTHER | 0 | Feb 18, 2019 | clinicaltrials |
| NCT02005419 | Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | completed | Phase 2 | 300 | Xian-Jun YuOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02023021 | Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | completed | Phase 2 | 80 | Xian-Jun YuOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03239184 | Bioinformation Therapy for Pancreatic Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT00438256 | Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03807999 | Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer | completed | Phase 2 | 125 | Hacettepe UniversityOTHER | 0 | Jan 17, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | completed | Phase 1 / Phase 2 | 28 | Halozyme TherapeuticsINDUSTRY | 2 | Nov 30, 2018 | clinicaltrials |
| NCT03627390 | BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer | completed | Phase 2 | 16 | Meabco A/SINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00068432 | Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00460174 | Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01032057 | Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery(SCALOP) | completed | Phase 2 | 114 | Lisette NixonOTHER | 1 | Oct 26, 2018 | clinicaltrials |
| NCT00003677 | Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00557492 | Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer | completed | Phase 2 | 59 | Amer ZureikatOTHER | 1 | Sep 25, 2018 | clinicaltrials |
| NCT02399137 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer(CARRIE) | completed | Phase 2 | 88 | Merrimack PharmaceuticalsINDUSTRY | 6 | Sep 18, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT00078975 | 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer | completed | Phase 2 | 26 | University Health Network, TorontoOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT00109941 | Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery(OGF) | completed | Phase 2 | 25 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01534637 | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer | completed | Phase 2 | 22 | Wake Forest University Health SciencesOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT00408564 | Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 39 | Medical University of South CarolinaOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT02558868 | Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer | completed | Phase 2 | 80 | Zhejiang UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT01389440 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer(GEMCAD1003) | completed | Phase 2 | 24 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT01373164 | A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 170 | Eli Lilly and CompanyINDUSTRY | 6 | May 16, 2018 | clinicaltrials |
| NCT01417000 | Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer | completed | Phase 2 | 93 | Aduro Biotech, Inc.INDUSTRY | 1 | May 8, 2018 | clinicaltrials |
| NCT01458717 | Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer | completed | Phase 2 / Phase 3 | 58 | Seoul National University HospitalOTHER | 1 | May 2, 2018 | clinicaltrials |
| NCT02284139 | Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | completed | Phase 2 / Phase 3 | 90 | Dong-A University HospitalOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00839332 | A Study for Participants With Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | Eli Lilly and CompanyINDUSTRY | 6 | Apr 17, 2018 | clinicaltrials |
| NCT01888978 | Molecularly Tailored Therapy for Pancreas Cancer | completed | Phase 2 | 19 | Georgetown UniversityOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Sep 12, 2019source: clinicaltrials